New hope for brain cancer? radiation plus immunotherapy trial launches

NCT ID NCT05423210

First seen Jan 05, 2026 · Last updated Apr 28, 2026 · Updated 18 times

Summary

This early-phase trial is testing whether combining a precise type of radiation (FSRT) with an immunotherapy drug (atezolizumab) can help people with a fast-growing brain tumor called glioblastoma. Twelve newly diagnosed patients will receive the combination for two weeks before surgery to remove the tumor, then continue the drug after surgery. The goal is to see if this approach is safe and can delay the cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stony Brook University Hospital

    RECRUITING

    Stony Brook, New York, 11794, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.